Congenital abnormalities. by the numbers

Size: px
Start display at page:

Download "Congenital abnormalities. by the numbers"

Transcription

1 AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Congenital abnormalities by the numbers Congenital abnormalities are among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned by the American Academy of Dermatology. The report examined prevalence, economic burdens, and mortality for skin disease in the U.S. using 2013 health care claims data drawn from insurance enrollment and claims databases and found that: 84.5 million Americans one in four saw a physician for skin disease; 50% of them are over 65 and have an average of 2.2 skin conditions. Skin disease cost the U.S. healthcare system $75 billion in medical, preventative, and prescription and non-prescription drug costs. One in three Americans with skin disease were seen by a dermatologist, who collaborate with other physicians throughout the health care system in caring for these patients. More than 961,000 Americans sought medical treatment in 2013 related to congenital abnormalities of the skin, a category that includes a number of diseases including hemangiomas, ichthyosis congenita, vascular hamartomas, and congenital ectodermal dysplasia. Congenital abnormalities: Were more prevalent in children than adults. Resulted in $205 million in medical costs. Mean a potential decrease in lifespan of 20 years. The charts that follow provide topline data on how congenital abnormalitis contribute to the overall burden of skin disease. The full report includes data on prescription and non-prescription drug costs, and how age and insurance status and provider relate to the burden associated with congenital abnormalities and skin disease broadly. To purchase the report visit

2 Prevalance NUMBER OF CARED-FOR INDIVIDUALS 30,000,000 25,000,000 20,000,000 15,000,000 10,000,000 5,000, ,089 NON-CANCEROUS SKIN GROWTHS* VIRAL AND FUNGAL DISEASES WOUNDS AND BURNS CONTACT DERMATITIS * This category is clinically broad in nature and includes, among other diseases: benign neoplasms, melanocytic nevi (unspecified), pilar cysts, pilonidal cysts (with or without abscess), scars and fibrosis, etc. ABNORMALITY PATIENTS BY AGE* 40.0% 35.0% 34.9% 30.0% 25.0% 20.0% 22.2% 22.0% 20.8% 15.0% 0.34% 10.0% 5.0% 0.0% *Percentage of congenital aabnormality patients seen by a physician by age group.

3 Cost TOTAL MEDICAL COST* (IN MILLIONS USD) $9,000 $8,000 $7,000 $6,000 $5,000 $4,000 $3,000 $8,135 $7,015 $6,398 $6,052 $5,442 $2,000 $1,000 $0 $205 NON-CANCEROUS SKIN GROWTHS** WOUNDS AND BURNS SKIN CANCER*** ULCERS * In millions of dollars compared to most costly skin diseases. * *This category is clinically broad in nature and includes, among other diseases: benign neoplasms, melanocytic nevi (unspecified), pilar cysts, pilonidal cysts (with or without abscess), scars and fibrosis, etc. *** Represents combined data for melanoma and nonmelanoma skin cancer. COST OF SKIN DISEASE PER AFFECTED PERSON* $3, $3, $2, $2, $1, $1, $ $0.00 $ LYMPHOMA SKIN CANCER** ULCERS CONNECTIVE TISSUE DISEASES BULLOUS DISEASES *Compared with most costly skin diseases. ** Represents combined data for melanoma and nonmelanoma skin cancer.

4 Life Impact MORTALITY* 5,000 4,500 NUMBER OF DEATHS IN ,000 3,500 3,000 2,500 2,000 1,500 1, , Y 3, Y 2, Y 1, Y 1, Y Y SKIN CANCER** WOUNDS AND BURNS ULCERS CONNECTIVE TISSUE DISEASES * Provides the total number of deaths and average age at death from congenital abnormalities compared with other skin diseases with highest mortality. ** Represents combined data for melanoma and nonmelanoma skin cancer. YEARS OF POTENTIAL LIFE LOST* TOTAL SKIN DISEASES ALL CAUSES OF DEATH ALL CAUSES OF DEATH TOTAL SKIN DISEASES WOUNDS AND BURNS CONNECTIVE TISSUE DISEASES 7.9 YEARS * Estimate/projected number of life years lost due to congenital abnormalities compared to top skin diseases leading to early death; Projected based on prototypical lifespan of 75 years.

5 Life Impact (cont d) LOST PRODUCTIVITY (OPPORTUNITY COST)* $2,500 (IN MILLIONS USD) $2,000 $1,500 $1,000 $1,924 $1,570 $1,413 $940 $699 $500 $0 $34 NON-CANCEROUS WOUNDS SKIN GROWTHS** AND BURNS VIRAL AND FUNGAL DISEASE CONTACT DERMATITIS * Time lost by patients and/or caregivers multiplied by average wages in 2013 ($192/day); In millions of dollars compared with skin diseases leading to the most loss of productivity. * *This category is clinically broad in nature and includes, among other diseases: benign neoplasms, melanocytic nevi (unspecified), pilar cysts, pilonidal cysts (with or without abscess), scars and fibrosis, etc.

6 This information is intended for personal/noncommercial use and may not be reproduced in any form by any means (electronic, mechanical, or other) or held in any information storage and retrieval systems without written permission from the publisher. Commercial use or distribution For information on obtaining copies of this publication or to license the content for distribution, please visit for details and to complete an application. REV 05/05/

Skin infections by the numbers

Skin infections by the numbers AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Skin infections by the numbers Skin infections are among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned

More information

Skin cancer by the numbers

Skin cancer by the numbers AMERICAN ACADEMY OF DERMATOLOGY DISEASE BRIEFS Skin cancer by the numbers Melanoma and nonmelanoma (basal and squamous cell carcinoma) skin cancers are among 24 skin diseases or disease categories examined

More information

Bullous diseases by the numbers

Bullous diseases by the numbers AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Bullous diseases by the numbers Bullous diseases are among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned

More information

Connective tissue diseases by the numbers

Connective tissue diseases by the numbers AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Connective tissue diseases by the numbers Connective tissue diseases are among 24 skin diseases or disease categories examined in the Burden of Skin

More information

Contact dermatitis by the numbers

Contact dermatitis by the numbers AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Contact dermatitis by the numbers Contact dermatitis is among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned

More information

Rosacea by the numbers

Rosacea by the numbers AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Rosacea by the numbers Rosacea is among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned by the American

More information

Psoriasis by the numbers

Psoriasis by the numbers AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Psoriasis by the numbers Psoriasis is among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned by the

More information

Acne by the numbers. The charts that follow provide topline data on how acne contributes to the overall burden of skin disease.

Acne by the numbers. The charts that follow provide topline data on how acne contributes to the overall burden of skin disease. AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Acne by the numbers Acne is among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned by the American Academy

More information

Hair and nail disorders by the numbers

Hair and nail disorders by the numbers AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Hair and nail disorders by the numbers Hair and nail disorders are among 24 skin diseases or disease categories examined in the Burden of Skin Disease

More information

A Review of Medical Malpractice Claims from the CRICO Comparative Benchmarking System

A Review of Medical Malpractice Claims from the CRICO Comparative Benchmarking System A Review of Medical Malpractice Claims from the CRICO Comparative Benchmarking System (CBS: a national database of medical malpractice claims from captive & commercial insurers across the US ) Note: I

More information

Screening for malignant melanoma: a cost-effectiveness analysis Freedberg K A, Geller A C, Miller D R, Lew R A, Koh H K

Screening for malignant melanoma: a cost-effectiveness analysis Freedberg K A, Geller A C, Miller D R, Lew R A, Koh H K Screening for malignant melanoma: a cost-effectiveness analysis Freedberg K A, Geller A C, Miller D R, Lew R A, Koh H K Record Status This is a critical abstract of an economic evaluation that meets the

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Policy: Atopic Dermatitis and Topical Antipsoriatics Reference Number: TCHP.PHAR.18004 Effective Date: 01.01.18 Last Review Date: 10.12.18 Line of Business: Oregon Health Plan Revision Log See Important

More information

The Healthcare Cost of Symptomatic Congenital CMV Disease in Privately Insured US Children: Estimates from Administrative Claims Data

The Healthcare Cost of Symptomatic Congenital CMV Disease in Privately Insured US Children: Estimates from Administrative Claims Data National Center on Birth Defects and Developmental Disabilities The Healthcare Cost of Symptomatic Congenital CMV Disease in Privately Insured US Children: Estimates from Administrative Claims Data Scott

More information

Asthma Management and the Allergist

Asthma Management and the Allergist Asthma Management and the Allergist Better Outcomes at Lower Cost Executive Summary AllergyandAsthmaRelief.org college.acaai.org/betteroutcomeslowercosts A substantial and growing body of published clinical

More information

WR SKIN. DERMATOLOGY

WR SKIN. DERMATOLOGY WR SKIN. DERMATOLOGY 1 Societies 11 History 13 Dictionaries. Encyclopaedias. Bibliographies Use for general works only. Classify with specific aspect 15 Classification. Nomenclature 16 Tables. Statistics

More information

ICD-10-CM Cornea. Type RT LT OU SINGLE CODE UNSPECIFIED. Acute atopic conjunctivitis H10.11 H10.12 H10.13 X H10.10

ICD-10-CM Cornea. Type RT LT OU SINGLE CODE UNSPECIFIED. Acute atopic conjunctivitis H10.11 H10.12 H10.13 X H10.10 ICD-10-CM Cornea Conjunctiva Acute atopic conjunctivitis H10.11 H10.12 H10.13 H10.10 Acute chemical conjunctivitis H10.211 H10.212 H10.213 H10.219 Acute conjunctivitis, unspecified H10.31 H10.32 H10.33

More information

BL-5010P A NOVEL PRE-FILLED APPLICATOR FOR THE NON-SURGICAL REMOVAL OF SKIN LESIONS

BL-5010P A NOVEL PRE-FILLED APPLICATOR FOR THE NON-SURGICAL REMOVAL OF SKIN LESIONS BL-5010P A NOVEL PRE-FILLED APPLICATOR FOR THE NON-SURGICAL REMOVAL OF SKIN LESIONS 25 Skin lesions Miri Seiberg, PhD 26 Skin lesions A part of the skin that has an abnormal growth or appearance compared

More information

DEPARTMENT OF DERMATOLOGY WALTER REED NATIONAL MILITARY MEDICAL CENTER BETHESDA MARYLAND

DEPARTMENT OF DERMATOLOGY WALTER REED NATIONAL MILITARY MEDICAL CENTER BETHESDA MARYLAND DEPARTMENT OF DERMATOLOGY WALTER REED NATIONAL MILITARY MEDICAL CENTER BETHESDA MARYLAND 20889-5600 04 October 2016 MEMORANDUM FOR DERMATOLOGY CLINIC PERSONNEL SUBJECT: Standard Operating Procedure for

More information

Re: MassHealth Section 1115 Demonstration Waiver Amendment Request, Section 4 ( Waiver Request )

Re: MassHealth Section 1115 Demonstration Waiver Amendment Request, Section 4 ( Waiver Request ) October 20, 2017 Eric Hargan Acting Secretary Department of Health and Human Services Hubert H. Humphrey Building 200 Independence Avenue, SW Washington, D.C. 20201 Re: MassHealth Section 1115 Demonstration

More information

The impact of pharmaceutical innovation on New Zealand cancer patients

The impact of pharmaceutical innovation on New Zealand cancer patients The impact of pharmaceutical innovation on New Zealand cancer patients Frank R. Lichtenberg, Ph.D Columbia University and National Bureau of Economic Research New medicines have helped people with cancer

More information

GSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/Centers: Research Methods:

GSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/Centers: Research Methods: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

UNDERSTANDING ATOPIC DERMATITIS IN THE US

UNDERSTANDING ATOPIC DERMATITIS IN THE US Key points: Resources for training general practitioners to treat atopic dermatitis (AD) remain sparse and inconsistent. A lack of comprehensive data makes it difficult to assess the prevalence of AD in

More information

VACAVILLE DERMATOLOGY

VACAVILLE DERMATOLOGY Connecting the Dots on those Spots NANDAN V. KAMATH, M.D. VACAVILLE DERMATOLOGY Sources All of the photos were taken with permission from the Dermnet NZ website - Dermnet New Zealand after communicating

More information

DERMATOLOGY ROTATION: COMPETENCY-BASED GOALS AND OBJECTIVES

DERMATOLOGY ROTATION: COMPETENCY-BASED GOALS AND OBJECTIVES UNC DIVISION OF PLASTIC AND RECONSTRUCTIVE SURGERY DERMATOLOGY ROTATION: COMPETENCY-BASED GOALS AND OBJECTIVES MEDICAL KNOWLEDGE A. Anatomy/Physiology/Embryology Goal: The resident will have knowledge

More information

Chapter 6: Healthcare Expenditures for Persons with CKD

Chapter 6: Healthcare Expenditures for Persons with CKD Chapter 6: Healthcare Expenditures for Persons with CKD In this 2017 Annual Data Report (ADR), we introduce information from the Optum Clinformatics DataMart for persons with Medicare Advantage and commercial

More information

Age-related prevalence of dermatoscopic patterns of acral melanocytic nevi

Age-related prevalence of dermatoscopic patterns of acral melanocytic nevi DERMATOLOGY PRACTICAL & CONCEPTUAL www.derm101.com Age-related prevalence of dermatoscopic patterns of acral melanocytic nevi Reiko Suzaki 1, Sumiko Ishizaki 1, Hitoshi Iyatomi 2, Masaru Tanaka 1 1 Department

More information

A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL

A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL OBJECTIVES Discuss current trends and changing concepts in our understanding of

More information

COSTS OF HEALTH SERVICES UTILIZATION OF PEOPLE WITH FETAL ALCOHOL SPECTRUM DISORDER BY SEX AND AGE GROUP IN ALBERTA, CANADA

COSTS OF HEALTH SERVICES UTILIZATION OF PEOPLE WITH FETAL ALCOHOL SPECTRUM DISORDER BY SEX AND AGE GROUP IN ALBERTA, CANADA COSTS OF HEALTH SERVICES UTILIZATION OF PEOPLE WITH FETAL ALCOHOL SPECTRUM DISORDER BY SEX AND AGE GROUP IN ALBERTA, CANADA Nguyen Xuan Thanh 1,2, Egon Jonsson 1,2,3 1 Institute of Health Economics, Edmonton,

More information

Impact of Chronic Conditions on Health-Related Quality of Life

Impact of Chronic Conditions on Health-Related Quality of Life BURDEN OF ILLNESS Overview Impact of Chronic Conditions on Health-Related Quality of Life Chronic joint pain conditions have an important impact on health-related quality of life Note: a larger negative

More information

The ALS Association Mid-America Chapter 87 people in Nebraska have ALS. Every 90 minutes, someone is diagnosed with or passes away from ALS.

The ALS Association Mid-America Chapter 87 people in Nebraska have ALS. Every 90 minutes, someone is diagnosed with or passes away from ALS. HEALTH FACTS The ALS Association Mid-America Chapter 87 people in Nebraska have ALS. Every 90 minutes, someone is diagnosed with or passes away from ALS. Alzheimer s Association Nebraska Chapter 5.5 million

More information

VARIATIONS IN PRICES AND REIMBURSEMENT OF MEDICINES IN THE EUROPEAN UNION

VARIATIONS IN PRICES AND REIMBURSEMENT OF MEDICINES IN THE EUROPEAN UNION VARIATIONS IN PRICES AND REIMBURSEMENT OF MEDICINES IN THE EUROPEAN UNION A snapshot of data on amoxicillin, budesonide, losartan and salbutamol in eight European Union Member States Report INTRODUCTION

More information

Principles of Anatomy and Physiology

Principles of Anatomy and Physiology Principles of Anatomy and Physiology 14 th Edition CHAPTER 5 The Integumentary System Introduction The organs of the integumentary system include the skin and its accessory structures including hair, nails,

More information

Drug Overdose Morbidity and Mortality in Kentucky,

Drug Overdose Morbidity and Mortality in Kentucky, Drug Overdose Morbidity and Mortality in Kentucky, 2000-2010 An examination of statewide data, including the rising impact of prescription drug overdose on fatality rates, and the parallel rise in associated

More information

Calculate a Fraction of a Whole Number

Calculate a Fraction of a Whole Number Calculate a Fraction of a Whole Number Objective: Calculate a fraction of a whole number Terms and Conditions To the best of the producer's knowledge, the academic content of this resource is accurate

More information

US Wound Dressing Market Size, Share, Growth, Industry Analysis, Competitive Strategies and Forescast to 2024 Hexa Research

US Wound Dressing Market Size, Share, Growth, Industry Analysis, Competitive Strategies and Forescast to 2024 Hexa Research US Wound Dressing Market Size, Share, Growth, Industry Analysis, Competitive Strategies and Forescast to 2024 Hexa Research The U.S. wound dressing market size was valued at USD 3.18 billion in 2017. Increasing

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.HNMC.27 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.HNMC.27 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC Clinical Policy: (Opdivo) Reference Number: CP.HNMC.27 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for

More information

Table 1: One Year Net Survival Rates for All Cancers Excluding Non-Melanoma Skin Cancer:

Table 1: One Year Net Survival Rates for All Cancers Excluding Non-Melanoma Skin Cancer: Task 1: Draw a bar chart of the following data. All the data must be on one graph. The data shows yearly survival rates for all types of cancers combined (except non-melanoma skin cancer). Hint: Each period

More information

DESCRIPTIONS FOR MED 3 ROTATIONS Dermatology A3S

DESCRIPTIONS FOR MED 3 ROTATIONS Dermatology A3S Regardless of your future field of practice, you will be exposed to a considerable amount of dermatology and this rotation provides you the chance to see a range of skin diseases. You will have the opportunity

More information

ETG Analyzer Report. Your Practice # Episodes. Mkt Share Mkt Volume WHIO Dermatology 575 Acne 746 $508 1,698 $

ETG Analyzer Report. Your Practice # Episodes. Mkt Share Mkt Volume WHIO Dermatology 575 Acne 746 $508 1,698 $ ETG Analyzer Report Practice: Practice Group: Badger County Severity: Level 1 Payers: Commercial Episode Types: Complete Claims: Full Claims Outliers: No Outliers DMV6 Created: April 1, 2010 March 31,

More information

Basics in Dermoscopy

Basics in Dermoscopy Basics in Dermoscopy Manal Bosseila Professor of Dermatology, Cairo University Member of European Academy Dermatology & Venereology EADV Member of International Dermoscopy Society IDS Member of Aesthetic

More information

Punch 1/25/2017. Coding for Biopsies. Jeffrey D. Lehrman, DPM, FASPS, FACFAS, MAPWCA. APMA Coding Committee. Editorial Advisory Board, WOUNDS

Punch 1/25/2017. Coding for Biopsies. Jeffrey D. Lehrman, DPM, FASPS, FACFAS, MAPWCA. APMA Coding Committee. Editorial Advisory Board, WOUNDS Coding for Biopsies Jeffrey D. Lehrman, DPM, FASPS, FACFAS, MAPWCA APMA Coding Committee Editorial Advisory Board, WOUNDS Board of Directors, American Society of Podiatric Surgeons Board of Directors,

More information

Setting the stage for change: upgrading the physician cancer case reporting application in New York

Setting the stage for change: upgrading the physician cancer case reporting application in New York Setting the stage for change: upgrading the physician cancer case reporting application in New York April Austin New York State Cancer Registry (NYSCR) July 12, 2018 June 13, 2018 Aerial view of Thousand

More information

Annual High Claims Survey. Year Ending 31 December 2016

Annual High Claims Survey. Year Ending 31 December 2016 Annual High Claims Survey Year Ending 31 December 2016 Released July 2017 Summary The Private Healthcare Australia Annual High Claims Survey Report analyses the nature and magnitude of high claims met

More information

The Cost Of Functional Dyspepsia Results From A Large US Employer Database

The Cost Of Functional Dyspepsia Results From A Large US Employer Database European ISPOR Meeting Copenhagen, Denmark October 30, 2006 The Cost Of Functional Dyspepsia Results From A Large US Employer Database Researchers: Stephen George, MS, RPh 1, Nathan Kleinman, PhD 2, Richard

More information

THE COST OF DIABETES IN ALBERTA

THE COST OF DIABETES IN ALBERTA THE COST OF DIABETES IN ALBERTA The Alberta Diabetes Cost Model 1 In 2009, the Canadian Diabetes Association commissioned a report, An Economic Tsunami: the Cost of Diabetes in Canada, to determine the

More information

Attending Physician s Statement

Attending Physician s Statement ( Form A A This form is used for claiming the social insurance benefit. This form should be completed and signed by the attending physician outpatient and One form for each month, one form for hospitalization

More information

PHA Annual High Claims Report 2018

PHA Annual High Claims Report 2018 24 October 2018 Medical device costs, increasing complexity and growing numbers of long hospital stays for mental health problems drive high health insurance claims PHA s Annual High Claims 2018 Report

More information

IT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY

IT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY IT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY Skin, Bones, and other Private Parts Symposium Dermatology Lectures by Debra Shelby, PhD, DNP, FNP-BC, FADNP, FAANP Debra Shelby,

More information

Contribution of health care factors to the burden of skin disease in the United States

Contribution of health care factors to the burden of skin disease in the United States FROM THE ACADEMY Contribution of health care factors to the burden of disease in the United States HenryW.Lim,MD, a ScottA.B.Collins,MD, b Jack S. Resneck, Jr, MD, c Jean L. Bolognia, MD, d Julie A. Hodge,

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: itraconazole (Sporanox) Reference Number: HIM.PA.36 Effective Date: 05/16 Last Review Date: Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important

More information

Miami-Dade County Prepaid Dental Health Plan Demonstration: Less Value for State Dollars

Miami-Dade County Prepaid Dental Health Plan Demonstration: Less Value for State Dollars Miami-Dade County Prepaid Dental Health Plan Demonstration: Less Value for State Dollars Analysis commissioned by The Collins Center for Public Policy / Community Voices Miami AUGUST 2006 Author: Burton

More information

Wound Management in Urgent Care

Wound Management in Urgent Care Wound Management in Urgent Care Brittany Busse Wound Management in Urgent Care Brittany Busse, MD Med 7 Urgent Care Folsom, CA, USA ISBN 978-3-319-27426-3 DOI 10.1007/978-3-319-27428-7 ISBN 978-3-319-27428-7

More information

Gastric ulcers at endoscopy: brush, biopsy, or both Sadowski D C, Rabeneck L

Gastric ulcers at endoscopy: brush, biopsy, or both Sadowski D C, Rabeneck L Gastric ulcers at endoscopy: brush, biopsy, or both Sadowski D C, Rabeneck L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract

More information

Global Influenza Vaccine Market: Industry Analysis & Outlook

Global Influenza Vaccine Market: Industry Analysis & Outlook Industry Research by Koncept Analytics Global Influenza Vaccine Market: Industry Analysis & Outlook ----------------------------------------- January 2017 1 Executive Summary Influenza, also known as flu,

More information

REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Protopic in the nine major pharmaceutical markets

More information

Source of effectiveness data The effectiveness evidence was derived from a review of published studies.

Source of effectiveness data The effectiveness evidence was derived from a review of published studies. Cost and cost effectiveness of venous and pressure ulcer protocols of care Kerstein M D, Gemmen E, van Rijswijk L, Lyder C H, Phillips T, Xakellis G, Golden K, Harrington C Record Status This is a critical

More information

2019 March. Tobacco Facts: Consumption, Mortality, and Morbidity. Center for Urban Population Health University of Wisconsin-Milwaukee

2019 March. Tobacco Facts: Consumption, Mortality, and Morbidity. Center for Urban Population Health University of Wisconsin-Milwaukee 2019 March Tobacco Facts: Consumption, Mortality, and Morbidity Center for Urban Population Health University of Wisconsin-Milwaukee ACKNOWLEDGEMENTS This report was prepared by Karen A. Palmersheim, Ph.D.,

More information

AUTISM SPEAKS RESOURCE IN PUBLIC HEALTH

AUTISM SPEAKS RESOURCE IN PUBLIC HEALTH AUTISM SPEAKS RESOURCE IN PUBLIC HEALTH Andy Shih, PhD Senior Vice President, Public Health & Inclusion Follow Me @ASAndyShih About Autism Speaks Mission Autism Speaks is dedicated to promoting solutions,

More information

Cost of Diabetes. Laura Keller Director State Advocacy AK CO HI ID MT ND OR SD WA WY

Cost of Diabetes. Laura Keller Director State Advocacy AK CO HI ID MT ND OR SD WA WY Cost of Diabetes Laura Keller Director State Advocacy AK CO HI ID MT ND OR SD WA WY Christopher Stanley, MD, MBA American Diabetes Association Colorado Advocacy Chair Vice President of Population Health

More information

GASTROINTESTINAL IMAGING STUDY GUIDE

GASTROINTESTINAL IMAGING STUDY GUIDE GASTROINTESTINAL IMAGING STUDY GUIDE Pharynx Diverticula Foreign bodies Trauma o Motility Disorders Esophagus Diverticula Trauma Esophagitis Barrett esophagus Rings, webs, and strictures Varices Benign

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Rayos) Reference Number: CP.CPA.273 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important

More information

The Economic Burden of Hypercholesterolaemia

The Economic Burden of Hypercholesterolaemia The Economic Burden of Hypercholesterolaemia November 2018 TABLE OF CONTENTS Acronyms 3 Executive Summary 4 Introduction 5 Approach 5 Structure of the report 5 Economic burden of hypercholesterolaemia

More information

Cancer Disparities in Arkansas: An Uneven Distribution. Prepared by: Martha M. Phillips, PhD, MPH, MBA. For the Arkansas Cancer Coalition

Cancer Disparities in Arkansas: An Uneven Distribution. Prepared by: Martha M. Phillips, PhD, MPH, MBA. For the Arkansas Cancer Coalition Cancer Disparities in Arkansas: An Uneven Distribution Prepared by: Martha M. Phillips, PhD, MPH, MBA For the Arkansas Cancer Coalition Table of Contents Page Burden of Cancer 3 Cancer Disparities 3 Cost

More information

REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Elidel in the major pharmaceutical markets: the

More information

Objectives. 1. Recognizing benign skin lesions. 2.Know which patients will likely need surgical intervention.

Objectives. 1. Recognizing benign skin lesions. 2.Know which patients will likely need surgical intervention. The Joy of Pediatric Skin Dr. Claire Sanger University of Kentucky Plastic & Reconstructive Surgery Objectives 1. Recognizing benign skin lesions 2.Know which patients will likely need surgical intervention.

More information

Measure #131 (NQF 0420): Pain Assessment and Follow-Up National Quality Strategy Domain: Community/Population Health*

Measure #131 (NQF 0420): Pain Assessment and Follow-Up National Quality Strategy Domain: Community/Population Health* Measure #131 (NQF 0420): Pain Assessment and Follow-Up National Quality Strategy Domain: Community/Population Health* *Please note that PQRS 131 is incorrectly listed under the Communication and Care Coordination

More information

Injury Chronic Disease Infant Mortality Maternal & Child Health Infectious Disease Life Expectancy

Injury Chronic Disease Infant Mortality Maternal & Child Health Infectious Disease Life Expectancy Visit WatchUsThrive.org to learn more Welcome to the Community Health Pathway of WeTHRIVE! SM Here you will find a brief Community Health Assessment for your community. This will provide you with health

More information

Dates to which data relate The effectiveness data were gathered from 1 July 1996 to 20 June No price year was reported.

Dates to which data relate The effectiveness data were gathered from 1 July 1996 to 20 June No price year was reported. Impact of first-line vs second-line antibiotics for the treatment of acute uncomplicated sinusitis Piccirillo J F, Mager D E, Frisse M E, Bophy R H, Goggin A Record Status This is a critical abstract of

More information

The cost-effectiveness of screening blood donors for malaria by PCR Shehata N, Kohli M, Detsky A

The cost-effectiveness of screening blood donors for malaria by PCR Shehata N, Kohli M, Detsky A The cost-effectiveness of screening blood donors for malaria by PCR Shehata N, Kohli M, Detsky A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion

More information

Pertussis in adolescents and adults: should we vaccinate Lee G M, LeBaron C, Murphy T V, Lett S, Schauer S, Lieu T A

Pertussis in adolescents and adults: should we vaccinate Lee G M, LeBaron C, Murphy T V, Lett S, Schauer S, Lieu T A Pertussis in adolescents and adults: should we vaccinate Lee G M, LeBaron C, Murphy T V, Lett S, Schauer S, Lieu T A Record Status This is a critical abstract of an economic evaluation that meets the criteria

More information

Effective Technology and Its Economic Benefits: The Case of Colonoscopy

Effective Technology and Its Economic Benefits: The Case of Colonoscopy Effective Technology and Its Economic Benefits: The Case of Colonoscopy Ross C. DeVol, Chief Research Officer Milken Institute The 2015 Dialogue for Action: Expanding Access Through Innovation Renaissance

More information

Per Capita Health Care Spending on Diabetes:

Per Capita Health Care Spending on Diabetes: Issue Brief #10 May 2015 Per Capita Health Care Spending on Diabetes: 2009-2013 Diabetes is a costly chronic condition in the United States, medical costs and productivity loss attributable to diabetes

More information

Health technology Lower-extremity amputation prevention strategies among individuals with diabetes.

Health technology Lower-extremity amputation prevention strategies among individuals with diabetes. Potential economic benefits of lower-extremity amputation prevention strategies in diabetes Ollendorf D A, Kotsanos J G, Wishner W J, Friedman M, Cooper T, Bittoni M, Oster G Record Status This is a critical

More information

NORTH CAROLINA STATE HEALTH PLAN FOR TEACHERS AND STATE EMPLOYEES

NORTH CAROLINA STATE HEALTH PLAN FOR TEACHERS AND STATE EMPLOYEES NORTH CAROLINA STATE HEALTH PLAN FOR TEACHERS AND STATE EMPLOYEES Using Clinical Risk Groups to Focus Board Strategic Initiatives July 26, 2013 Copyright 2013 by The Segal Group, Inc., parent of The Segal

More information

David B. Troxel, MD. Common Medicolegal Situations: Misdiagnosis of Melanoma

David B. Troxel, MD. Common Medicolegal Situations: Misdiagnosis of Melanoma Common Medicolegal Situations: Misdiagnosis of Melanoma David B. Troxel, MD Medical Director, The Doctors Company, Napa, California Clinical Professor Emeritus, University of California at Berkeley Past

More information

Virginia s Health 2017

Virginia s Health 2017 Virginia s Health 2017 Marissa J. Levine, MD, MPH, FAAFP Virginia State Health Commissioner The Virginia Department of Health HAC Health & Human Resources Subcommittee Overview Virginian s Health Status

More information

REVIEW MANAGEMENT. Clinical Review of Drugs to Reduce the Risk of Cancer CONTENTS

REVIEW MANAGEMENT. Clinical Review of Drugs to Reduce the Risk of Cancer CONTENTS REVIEW MANAGEMENT Clinical Review of Drugs to Reduce the Risk of Cancer CONTENTS PURPOSE BACKGROUND REFERENCES DEFINITIONS AND ACRONYMS POLICY PROCEDURES EFFECTIVE DATE PURPOSE This MAPP describes: The

More information

Cost-effectiveness of uterine artery embolization and hysterectomy for uterine fibroids Beinfeld M T, Bosch J L, Isaacson K B, Gazelle G S

Cost-effectiveness of uterine artery embolization and hysterectomy for uterine fibroids Beinfeld M T, Bosch J L, Isaacson K B, Gazelle G S Cost-effectiveness of uterine artery embolization and hysterectomy for uterine fibroids Beinfeld M T, Bosch J L, Isaacson K B, Gazelle G S Record Status This is a critical abstract of an economic evaluation

More information

Clinical Policy: Naloxone (Evzio) Reference Number: CP.PMN.139 Effective Date: Last Review Date: Line of Business: Commercial, Medicaid

Clinical Policy: Naloxone (Evzio) Reference Number: CP.PMN.139 Effective Date: Last Review Date: Line of Business: Commercial, Medicaid Clinical Policy: Naloxone (Evzio) Reference Number: CP.PMN.139 Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of

More information

LIFE INSURANCE COMPANIES TAKE LEAP OF FAITH

LIFE INSURANCE COMPANIES TAKE LEAP OF FAITH LIFE INSURANCE COMPANIES TAKE LEAP OF FAITH Cover for HIV positive and diabetic lives QED Actuaries & Consultants Craig Falconer 1 December 2017 OVERVIEW HIV Product Diabetes Product Key success Factors

More information

An Unhealthy America: The Economic Burden of Chronic Disease Charting a New Course to Save Lives and Increase Productivity and Economic Growth

An Unhealthy America: The Economic Burden of Chronic Disease Charting a New Course to Save Lives and Increase Productivity and Economic Growth An Unhealthy America: The Economic Burden of Chronic Disease Charting a New Course to Save Lives and Increase Productivity and Economic Growth Ross DeVol Director, Center for Health Economics Director,

More information

Clinical Policy: Ramucirumab (Cyramza) Reference Number: CP.HNMC.09 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC

Clinical Policy: Ramucirumab (Cyramza) Reference Number: CP.HNMC.09 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC Clinical Policy: (Cyramza) Reference Number: CP.HNMC.09 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy

More information

2017 Rhinoplasty Coding and Reimbursement Guide

2017 Rhinoplasty Coding and Reimbursement Guide 2017 Rhinoplasty Coding and Reimbursement Guide Profile Costal Cartilage Allograft A Pre-shaped costal cartilage allograft for rhinoplasty procedures HCPCS Description * Status Indicator APC HOPPS¹ ASC¹

More information

Associate Clinical Professor of Dermatology MUSC

Associate Clinical Professor of Dermatology MUSC Re-excision of Moderately Dysplastic Nevi: Should we or shouldn t we? John C. Maize, Jr, M.D. Dermatologist and Dermatopathologist Trident Dermatology, Charleston SC Associate Clinical Professor of Dermatology

More information

Radiation Therapy for Skin Cancer

Radiation Therapy for Skin Cancer Radiation Therapy for Skin Cancer Armand B. Cognetta Jr. William M. Mendenhall Editors Radiation Therapy for Skin Cancer Editors Armand B. Cognetta Jr. Dermatology Associates of Tallahassee Chief, Division

More information

Diabetic Foot Ulcers

Diabetic Foot Ulcers Economic burden of diabetic foot ulcers and amputations Diabetic Foot Ulcers Data Points #3 Diabetes mellitus is a significant illness, both from an individual point of view and a societal perspective.

More information

C-Change Making the Business Case Questions & Answers

C-Change Making the Business Case Questions & Answers C-Change Making the Business Case Questions & Answers How To Use This Document Following are a set of questions and answers about C-Change s multi-year Making the Business Case for cancer prevention and

More information

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY Measure #192 (NQF 0564): Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR

More information

The Cost of Diabetes in NEWFOUNDLAND & LABRADOR

The Cost of Diabetes in NEWFOUNDLAND & LABRADOR The Cost of Diabetes in NEWFOUNDLAND & LABRADOR The Cost of Diabetes in Newfoundland and Labrador The Newfoundland and Labrador Diabetes Cost Model 1 In 2009, the Canadian Diabetes Association commissioned

More information

SKIN LESIONS. On behalf of Airedale, Wharfedale and Craven CCG, Bradford City CCG and Bradford Districts CCG. Bradford and Airedale CCGs.

SKIN LESIONS. On behalf of Airedale, Wharfedale and Craven CCG, Bradford City CCG and Bradford Districts CCG. Bradford and Airedale CCGs. Bradford and Airedale CCGs SKIN LESIONS Version: 2 Ratified by: Date ratified: Author(s): Responsible Committee: Consultant in Public Health Individual Funding Request Panel Date issue: September 2013

More information

THE COST OF DIABETES IN BRITISH COLUMBIA

THE COST OF DIABETES IN BRITISH COLUMBIA THE COST OF DIABETES IN BRITISH COLUMBIA The British Columbia Diabetes Cost Model 1 In 2009, the Canadian Diabetes Association commissioned a report, An Economic Tsunami: the Cost of Diabetes in Canada,

More information

DISCLAIMER CONTRIBUTORS

DISCLAIMER CONTRIBUTORS DISCLAIMER The Addiction Technology Transfer Center Network prepared this publication under a cooperative agreement from the Substance Abuse and Mental Health Services Administration s (SAMHSA) Center

More information

Nature and significance of the local problem

Nature and significance of the local problem Revised Standards for Quality Improvement Reporting Excellence (SQUIRE 2.0) September 15, 2015 Text Section and Item Section or Item Description Name The SQUIRE guidelines provide a framework for reporting

More information

US Ambulatory Electrocardiography (ECG) Market: Industry Analysis & Outlook ( )

US Ambulatory Electrocardiography (ECG) Market: Industry Analysis & Outlook ( ) Industry Research by Koncept Analytics US Ambulatory Electrocardiography (ECG) Market: Industry Analysis & Outlook ----------------------------------------- January 2018 US Ambulatory Electrocardiography

More information

Drug Prior Authorization Form Opdivo (nivolumab)

Drug Prior Authorization Form Opdivo (nivolumab) This document contains both information and form fields. To read information, use the Down Arrow from a form field. Drug Prior Authorization Form The purpose of this form is to obtain information required

More information

SKIN SERVICES REVIEW Changes to Medicare Benefits Schedule for 1 November 2016

SKIN SERVICES REVIEW Changes to Medicare Benefits Schedule for 1 November 2016 Attachment A SKIN SERVICES REVIEW Changes to Medicare Benefits Schedule for 1 November 2016 Deleted items 31200-31215, 31230-31240 31255-31335 Colour Coding for new / updated items: MUCOSAL BIOPSY AND

More information

No one should be at risk of poor health because of their social and economic situations.

No one should be at risk of poor health because of their social and economic situations. HEALTH MATTERS No one should be at risk of poor health because of their social and economic situations. Members of municipal government play an important role in shaping policies that impact all aspects

More information

Clinical Policy: Implantable Miniature Telescope for Age Related Macular Degeneration Reference Number: CP.MP.517

Clinical Policy: Implantable Miniature Telescope for Age Related Macular Degeneration Reference Number: CP.MP.517 Clinical Policy: Implantable Miniature Telescope for Age Related Macular Reference Number: CP.MP.517 Effective Date: 11/16 Last Review Date: 11/17 See Important Reminder at the end of this policy for important

More information